Aided by “Clean” FDA Label, US Dermatologists Report BMS’ Sotyktu Has Potential to Delay Biologic Treatment in Plaque Psoriasis, According to Spherix Global Insights

Amgen's Otezla likely to face the most immediate impacts of increased Sotyktu adoption EXTON, Pa., Dec. 8, 2022 /PRNewswire/ -- On September 9, 2022, BMS announced the FDA approval of Sotyktu for moderate-to-severe plaque psoriasis (PsO), making it the first selective TKY2 inhibitor...

Click to view original post